Literature DB >> 1409890

Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells.

C Thomas1, R S Pardini.   

Abstract

The photodynamic effect of hypericin on EMT6 mouse mammary carcinoma cells was investigated in vitro under aerobic and hypoxic conditions. Under aerobic conditions, hypericin-induced photocytotoxicity was dose dependent within a 1-50 microM range. Under hypoxic conditions, cells were resistant to hypericin-induced phototoxicity. In the dark, no cytotoxicity was observed at any hypericin concentration tested either aerobically or hypoxically. Cellular accumulation of hypericin, examined by chemical extraction and spectroscopy, occurred under both hypoxic and aerobic conditions. Fluorescence photomicrographs of cells exposed to hypericin corroborate drug uptake in the plasma membrane and subcellular regions. Our results demonstrate that hypericin cytotoxicity to EMT6 mouse mammary carcinoma cells in vitro is both light and oxygen-dependent. These results suggest that EMT6 cell kill caused by photoactivated hypericin is mediated by an oxygen-dependent mechanism, rather than by a type I oxygen-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409890     DOI: 10.1111/j.1751-1097.1992.tb08531.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  16 in total

1.  Photodynamic efficacy of hypericin targeted by two delivery techniques to hepatocellular carcinoma cells.

Authors:  Maha Fadel; Kawser Kassab; Tareq Youssef
Journal:  Lasers Med Sci       Date:  2010-09       Impact factor: 3.161

2.  Growth inhibition of malignant glioblastoma by DING protein.

Authors:  Markus J Bookland; Nune Darbinian; Michael Weaver; Shohreh Amini; Kamel Khalili
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

3.  Near-infrared Transillumination and Photodynamic Therapy Using Hypericin in Animal Laryngeal Tumors.

Authors:  Haeyoung Lee; Sung Won Kim; Daa Young Kwon; Hyun Wook Kang; Min-Jung Jung; Jun Hyeong Kim; Yeh-Chan Ahn; Chulho Oak
Journal:  Tissue Eng Regen Med       Date:  2021-09-08       Impact factor: 4.451

Review 4.  Hypericins as potential leads for new therapeutics.

Authors:  Anastasia Karioti; Anna Rita Bilia
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

5.  Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight.

Authors:  S Carpenter; M J Fehr; G A Kraus; J W Petrich
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

6.  Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.

Authors:  Chad D Cole; James K Liu; Xiaoming Sheng; Steven S Chin; Meic H Schmidt; Martin H Weiss; William T Couldwell
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

7.  Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.

Authors:  Junjie Li; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  J Cancer       Date:  2013-01-22       Impact factor: 4.207

8.  A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: possible relevance to photodynamic therapy.

Authors:  G Lavie; C Kaplinsky; A Toren; I Aizman; D Meruelo; Y Mazur; M Mandel
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Photodynamic effect of hypericin on the conformation and catalytic activity of hemoglobin.

Authors:  Jing Zhao; Wenying Meng; Peng Miao; Zhiguo Yu; Genxi Li
Journal:  Int J Mol Sci       Date:  2008-02-05       Impact factor: 6.208

10.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.